Artivion, Inc. (NYSE:AORT) Stake Lowered by Calamos Advisors LLC

Calamos Advisors LLC lessened its position in Artivion, Inc. (NYSE:AORT - Free Report) by 14.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,000 shares of the company's stock after selling 9,029 shares during the period. Calamos Advisors LLC owned about 0.13% of Artivion worth $1,327,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of AORT. Peregrine Capital Management LLC purchased a new stake in Artivion in the 1st quarter worth approximately $7,650,000. Wasatch Advisors LP increased its stake in Artivion by 27.7% in the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock valued at $29,791,000 after purchasing an additional 226,160 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Artivion during the fourth quarter worth about $5,573,000. First Trust Advisors LP purchased a new position in Artivion during the fourth quarter worth about $4,771,000. Finally, Next Century Growth Investors LLC boosted its stake in Artivion by 29.7% in the 4th quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company's stock worth $14,085,000 after buying an additional 112,918 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Analysts Set New Price Targets

AORT has been the topic of several recent analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $32.00 price objective on shares of Artivion in a report on Tuesday, May 6th. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Canaccord Genuity Group initiated coverage on Artivion in a report on Tuesday, June 17th. They set a "buy" rating and a $35.00 price objective for the company. Finally, JMP Securities reiterated a "market outperform" rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $32.40.

Insider Buying and Selling at Artivion

In other news, SVP Marshall S. Stanton sold 15,000 shares of the stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $29.50, for a total transaction of $442,500.00. Following the transaction, the senior vice president owned 64,200 shares of the company's stock, valued at approximately $1,893,900. This trade represents a 18.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jean F. Holloway sold 8,748 shares of Artivion stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $29.00, for a total value of $253,692.00. Following the completion of the transaction, the senior vice president owned 178,510 shares of the company's stock, valued at approximately $5,176,790. The trade was a 4.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,954 shares of company stock valued at $2,108,525 over the last 90 days. 7.60% of the stock is owned by corporate insiders.

Artivion Stock Down 1.6%

Shares of NYSE:AORT traded down $0.50 during midday trading on Monday, hitting $30.22. 304,276 shares of the company's stock traded hands, compared to its average volume of 337,493. The firm's fifty day moving average price is $28.73 and its two-hundred day moving average price is $27.58. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.95 and a current ratio of 5.53. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $32.33. The company has a market cap of $1.29 billion, a PE ratio of -60.44 and a beta of 1.62.

Artivion (NYSE:AORT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). The company had revenue of $98.98 million during the quarter, compared to analysts' expectations of $94.81 million. Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. On average, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.